STAT3 and posterior cortical atrophy: In light of the evidence pinpointing primed activation of the EGFR‐STAT3 pathway in PCa cells with ETV1 overexpression, we thus explored the antitumorigenic potential of a therapy combining Erlotinib and TTI‐101, as EGFR and STAT3 inhibitors, for the treatment of ETV1‐positive PCa.